Sagimet Biosciences Inc. Interest and Other Income
Sagimet Biosciences Inc. (SGMT) reported Interest and Other Income of $1.86 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Other Income
us-gaap:InterestAndOtherIncome · last filed 2026-08-11
- Sagimet Biosciences Inc. interest and other income for the quarter ending 2026-06-30 was $1.86M, a 21.18% increase year-over-year.
- Sagimet Biosciences Inc. interest and other income for the quarter ending 2026-03-31 was $1.06M, a 37.06% decline year-over-year.
- Sagimet Biosciences Inc. interest and other income for the quarter ending 2025-12-31 was $1.20M, a 39.97% decline year-over-year.
- Sagimet Biosciences Inc. interest and other income for the quarter ending 2025-09-30 was $1.43M, a 37.54% decline year-over-year.
- Sagimet Biosciences Inc. interest and other income for fiscal 2025 was $5.85M, a 34.16% decline from fiscal 2024.
- Sagimet Biosciences Inc. interest and other income for fiscal 2024 was $8.89M, a 210.73% increase from fiscal 2023.
- Sagimet Biosciences Inc. interest and other income for fiscal 2023 was $2.86M, a 417.18% increase from fiscal 2022.
- Sagimet Biosciences Inc. interest and other income for fiscal 2022 was $553.00K.
| Period end | Interest and Other Income 3 month | Interest and Other Income 3 month as first filed | Interest and Other Income 6 month | Interest and Other Income 6 month as first filed | Interest and Other Income 9 month | Interest and Other Income 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1.86M 10-Q · filed 2026-08-11 | $2.93M 10-Q · filed 2026-08-11 | $4.13M derived: sum of 3 quarters · filed 2026-08-11 | $5.55M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2026-03-31 | $1.06M 10-Q · filed 2026-05-12 | $2.26M derived: sum of 2 quarters · filed 2026-05-12 | $3.69M derived: sum of 3 quarters · filed 2026-05-12 | $5.22M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2025-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $2.62M derived: sum of 2 quarters · filed 2026-03-11 | $4.16M derived: sum of 3 quarters · filed 2026-08-11 | $5.85M 10-K · filed 2026-03-11 | ||
| 2025-09-30 | $1.43M 10-Q · filed 2025-11-13 | $2.96M derived: sum of 2 quarters · filed 2026-08-11 | $4.65M 10-Q · filed 2025-11-13 | $6.65M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2025-06-30 | $1.54M 10-Q · filed 2026-08-11 | $3.23M 10-Q · filed 2026-08-11 | $5.22M derived: sum of 3 quarters · filed 2026-08-11 | $7.50M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2025-03-31 | $1.69M 10-Q · filed 2026-05-12 | $3.68M derived: sum of 2 quarters · filed 2026-05-12 | $5.97M derived: sum of 3 quarters · filed 2026-05-12 | $8.44M derived: sum of 4 quarters · filed 2026-05-12 | ||
| 2024-12-31 | $1.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $4.28M derived: sum of 2 quarters · filed 2026-03-11 | $6.75M derived: sum of 3 quarters · filed 2026-03-11 | $8.89M 10-K · filed 2026-03-11 | ||
| 2024-09-30 | $2.28M 10-Q · filed 2025-11-13 | $4.75M derived: sum of 2 quarters · filed 2025-11-13 | $6.89M 10-Q · filed 2025-11-13 | $8.21M derived: sum of 4 quarters · filed 2025-11-13 | ||
| 2024-06-30 | $2.47M 10-Q · filed 2025-08-13 | $4.61M 10-Q · filed 2025-08-13 | $5.92M derived: sum of 3 quarters · filed 2025-08-13 | $7.02M derived: sum of 4 quarters · filed 2025-08-13 | ||
| 2024-03-31 | $2.14M 10-Q · filed 2025-05-08 | $3.45M derived: sum of 2 quarters · filed 2025-05-08 | $4.55M derived: sum of 3 quarters · filed 2025-05-08 | $4.82M derived: sum of 4 quarters · filed 2025-05-08 | ||
| 2023-12-31 | $1.31M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $2.41M derived: sum of 2 quarters · filed 2025-03-12 | $2.68M derived: sum of 3 quarters · filed 2025-03-12 | $2.86M 10-K · filed 2025-03-12 | ||
| 2023-09-30 | $1.09M 10-Q · filed 2024-11-14 | $1.37M derived: sum of 2 quarters · filed 2024-11-14 | $1.55M 10-Q · filed 2024-11-14 | $1.74M derived: sum of 4 quarters · filed 2024-11-14 | ||
| 2023-06-30 | $272.00K 10-Q · filed 2024-08-14 | $271.00K 10-Q · filed 2023-08-21 | $450.00K 10-Q · filed 2024-08-14 | $451.00K 10-Q · filed 2023-08-21 | $645.00K derived: sum of 3 quarters · filed 2024-08-14 | $863.00K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $180.00K 10-Q · filed 2024-05-15 | $373.00K derived: sum of 2 quarters · filed 2024-05-15 | $591.00K derived: sum of 3 quarters · filed 2024-05-15 | $727.00K derived: sum of 4 quarters · filed 2024-05-15 | ||
| 2022-12-31 | $193.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $411.00K derived: sum of 2 quarters · filed 2024-03-25 | $547.00K derived: sum of 3 quarters · filed 2024-03-25 | $553.00K 10-K · filed 2024-03-25 | ||
| 2022-09-30 | $218.00K 10-Q · filed 2023-11-13 | $354.00K derived: sum of 2 quarters · filed 2023-11-13 | $360.00K 10-Q · filed 2023-11-13 | |||
| 2022-06-30 | $136.00K 10-Q · filed 2023-08-21 | $142.00K 10-Q · filed 2023-08-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |